Dr. Jacques Elion is a Professor of Biochemistry and Molecular Biology at Paris Diderot University Medical School. Dr. Elion is Director of the Department of Medical Genetics at Robert Debré Mother and Child University Hospital, Paris. He is Director of Research Unit 763 at the French National Institute of Health and Medical Research (Inserm), Paris, France and Guadeloupe, French West Indies.
Dr. Elion received his medical degree from the Paris Descartes University Medical School (1974) and a PhD from Paris Diderot University (1981).
He held the position of Research Assistant in Hematology Research at Mayo Graduate School of Medicine, University Minnesota (1976-1977). He also held a Fogarty Visiting Scientist position with the Section of Molecular Biology and Genetics, The National Institutes of Health (1985-1986).
Dr. Elion’s research is focused on the pathophysiology of sickle cell disease (SCD) and the identification of new therapeutic targets. His studies have identified several genetic markers contributing to the clinical variability of the disease. His work has demonstrated the pleiotropic action of hydroxyurea, the only drug demonstrated to be effective in SCD, on several cellular targets besides the erythroid lineage, including endothelial cells and polymorphonuclear neutrophils, and on the expression of an extended range of molecules involved in cell adhesion, vascular tone, and inflammatory mediators.
His clinical laboratory-based research is focused on other genetic anemias including rare abnormalities of erythropoiesis, red blood cell membrane, and enzymatic defects.
Dr. Elion is the author of 240 articles published in international scientific and medical journals.
He has been involved in a large number of scientific collaborations with many countries in the developing world, most notably in Africa, India, the Caribbean, and Brazil.
Dr. Elion’s clinical laboratory is one of the four centers of the French national program for newborn screening for SCD. It is part of the French National Reference Centre for sickle cell syndromes and rare genetic anemias.